Zobrazeno 1 - 10
of 33 094
pro vyhledávání: '"PD‐1"'
Autor:
Yufeng Shang, Guopeng Chen, Li Liu, Ruiyang Pan, Xinqi Li, Hui Shen, Yuxin Tan, Linlu Ma, Xiqin Tong, Weida Wang, Xiaoqin Chen, Zhongjun Xia, Xiaoyan Liu, Fuling Zhou
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract At present, the characteristics of double-hit multiple myeloma (DHMM) are unknown. We retrospectively analyzed the clinical data from 433 new diagnosed MM patients and found that DHMM have a higher β2-MG level and percentage of bone marrow
Externí odkaz:
https://doaj.org/article/79c965582c8b4c9da66af54724a3133a
Autor:
Feng Bi, Jian Dong, Chuan Jin, Zuoxing Niu, Wenhui Yang, Yifu He, Dajun Yu, Meili Sun, Teng Wang, Xianli Yin, Ruixing Zhang, Kehe Chen, Keming Wang, Zhiwu Wang, Wei Li, Zhongtao Zhang, Hangyu Zhang, Qunyi Guo, Xin Wang, Lei Han, Xizhi Zhang, Wei Shen, Liangming Zhang, Jieer Ying, Miao Wu, Weiguo Hu, Zeng Li, Xiaofen Li, Wenlei Feng, Baihui Zhang, Lingyan Li, Xiaoyan Kang, Weijian Guo
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Though several anti-PD-1/PD-L1 antibodies approved for monotherapy in microsatellite instability-high or mismatch repair-deficient unresectable/metastatic solid tumors, novel immunotherapy with better anti-tumor activity is needed in clinic.
Externí odkaz:
https://doaj.org/article/8fd5e3d042aa43cb9686e651183b4ed5
Autor:
Hongxin Li, Wen Zhao, Chengming Li, Hongchang Shen, Meiying Li, Chengjun Wang, Chunyan Han, Cuihua Yi, Jun Wang, Xue Meng, Lian Liu, Shuwen Yu, Jisheng Li
Publikováno v:
Thoracic Cancer, Vol 15, Iss 32, Pp 2327-2338 (2024)
Abstract Background For patients with advanced non‐small cell lung cancer (NSCLC) who have received frontline immunochemotherapy, subsequent treatment options are limited. As the first dual programmed cell death‐1 (PD‐1)/cytotoxic T lymphocyte
Externí odkaz:
https://doaj.org/article/a61e588278014004a470ed951b5d99f0
Autor:
Kadir Çorbacı, Meryem Gunay Gurleyik, Aylin Gonultas, Fugen Aker, Mehmet Onur Gul, Metin Tilki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract With a 5-year survival of ˂ 10%, pancreatic cancer is one of the leading causes of cancer-related deaths. Given the role of the distribution of tumor-infiltrating lymphocyte (TILs) subtypes in the tumor and its microenvironment in predictin
Externí odkaz:
https://doaj.org/article/c61260a562be4007914c9d6190ca9d0e
Autor:
Amjad Zafar, Asma Abdul Rashid, Abdul Moeed, Muhammad Junaid Tahir, Ahmad Jamal Khan, Oadi N. Shrateh, Ali Ahmed
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Malignant mesothelioma is an aggressive cancer with poor prognosis. Programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) have recently presented as a viable option in some first line
Externí odkaz:
https://doaj.org/article/d592ec5c48a14e32a654b169fb6c9bfe
Autor:
Joao Gorgulho, Sven H. Loosen, Ramsha Masood, Franziska Giehren, Francesca Pagani, Gustav Buescher, Lorenz Kocheise, Vincent Joerg, Constantin Schmidt, Kornelius Schulze, Christoph Roderburg, Eva Kinkel, Britta Fritzsche, Simon Wehmeyer, Benjamin Schmidt, Paul Kachel, Christina Rolling, Julian Götze, Alina Busch, Marianne Sinn, Thais Pereira-Veiga, Harriet Wikman, Maria Geffken, Sven Peine, Urte Matschl, Markus Altfeld, Samuel Huber, Ansgar W. Lohse, Fabian Beier, Tim H. Brümmendorf, Carsten Bokemeyer, Tom Luedde, Johann von Felden
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-15 (2024)
Abstract Background The major breakthrough in cancer therapy with immune checkpoint inhibitors (ICIs) has highlighted the important role of immune checkpoints in antitumoral immunity. However, most patients do not achieve durable responses, making bi
Externí odkaz:
https://doaj.org/article/c2fb5d5ae25641debf5ff764186a0fca
Publikováno v:
Biologics: Targets & Therapy, Vol Volume 18, Pp 313-326 (2024)
Hai-Li Wang,1 Shi-Xia Zhou,1 Jing Kuang,1 Sa Xiao,1 Min Li2 1Department of Oncology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, People’s Republic of China; 2Department of Oncology, Zhengzhou People’s Hospital, Zhen
Externí odkaz:
https://doaj.org/article/555d40dc1cc54df4818ab6092069858f
Publikováno v:
JAAD Case Reports, Vol 53, Iss , Pp 170-173 (2024)
Externí odkaz:
https://doaj.org/article/4586b76302344b45a4b47612bce5a77a
Autor:
Wenchang Zhou, Mengdi Qu, Ying Yue, Ziwen Zhong, Ke Nan, Xingfeng Sun, Qichao Wu, Jie Zhang, Wankun Chen, Changhong Miao
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-19 (2024)
Abstract Background Programmed cell death protein 1 (PD-1) blockade is essential in treating progressive colorectal cancer (CRC). However, some patients with CRC do not respond well to immunotherapy, possibly due to the exhaustion of CD8+ T cells in
Externí odkaz:
https://doaj.org/article/08cae4454219400b8c151d78ebbc6de4
Autor:
Yuichi Akama, Eun Jeong Park, Naoko Satoh‐Takayama, Atsushi Ito, Eiji Kawamoto, Arong Gaowa, Eri Matsuo, Satoshi Oikawa, Masafumi Saito, Shigeaki Inoue, Takayuki Akimoto, Kei Suzuki, Motomu Shimaoka
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 5, Pp 1999-2012 (2024)
Abstract Background Intensive care unit‐acquired weakness (ICU‐AW) is a syndrome characterized by a long‐term muscle weakness often observed in sepsis‐surviving patients during the chronic phase. Although ICU‐AW is independently associated
Externí odkaz:
https://doaj.org/article/1d156fea510b4154817590ed70147ae2